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OBJECTIVES: Health care costs incurred for particular
diseases express priorities and can show future directions
for targeting resources. Because these costs are difﬁcult 
to obtain, there are hardly any reliable estimates in
Germany. The analysis intends to show a new approach
to estimate expenditures for CHD borne by the statutory
health insurance in Germany. METHODS: We identiﬁed
roughly 4 million individuals by pre-selected indicator
medications for ﬁve different diseases namely asthma,
diabetes, heart failure, hypertension and CHD. Individu-
als were selected for inclusion if these indicator medica-
tions were administered to them at least once in the year
1999. Indicator medications for CHD were nitrates and
molsidomine. Expenditures for individuals with CHD
were compared to average age- and gender-speciﬁc expen-
ditures for individuals without CHD. To ﬁnd the portion
of the difference, which could be attributed to CHD on
the one hand and to other diseases on the other hand, 
the strong correlation of disease occurrence was
accounted for in a stepwise procedure. RESULTS:
Approximately half of the cost difference between CHD-
cases and non-CHD cases could be explained by the pres-
ence of CHD and the other half by concurrent diseases.
The total costs attributed to CHD sum up to some $5
billion. As a whole the statutory health insurance spends
roughly $130 billion per year. CONCLUSIONS: Com-
pared with the total health care budget, CHD accounts
for roughly 4% of health care expenditures if inter-disease
correlations are considered. This amount seems low given
the fact that CHD accounts for more than 20% of deaths
in Germany. The strong interactivity of disease concern-
ing health care costs might imply that they should not be
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OBJECTIVES: To compare hospital, procedural, and
ambulatory hypertension costs across eight countries
(Australia, Canada, France, Germany, Italy, Spain, UK
and the US) and document factors to consider when
making multinational comparisons. METHODS: Data
was obtained from health economics resources in each
country and an international literature search. Public and
private sources such as UK’s Royal London NHS Trust,
Personal Social Services Research Unit, and NHS Execu-
tive were used. Data tables captured four hypertension-
related events: Acute Myocardial Infarct (AMI),
Congestive Heart Failure (CHF), Stroke, and Renal
Failure (RF). All costs were converted into US Dollars for
the year 2000. RESULTS: There are considerable inter-
national variations in the hospitalization, procedural and
ambulatory hypertension treatment costs. These differ-
ences can be explained partially by the source of payment,
measurement of overhead, physician and hotel fees, and
prevailing practice patterns, as well as whether account-
ing costs or actual expenditures were used. US costs
appear to be higher for AMI, stroke and renal failure hos-
pitalizations, while CHF hospitalization costs are similar
across countries. The reported AMI hospitalization cost,
as a percentage of the US cost, ranges from 7.1% (UK)
to 43.5% (Spain). The UK and Australia appear to have
the lowest hospital-related and ambulatory costs across
all four events. Ambulatory costs for 1 year after an AMI,
CHF, transplantation or stroke hospitalization are highest
in the US. Typically the procedural and line item costs
were higher in the US than in other countries. Reported
CABG procedure costs ranged from 2.6% (France) to
51.8% (Italy) of US costs. CONCLUSIONS: We found
wide variation in captured and reported costs for hyper-
tension-related hospitalizations, procedures, and ambula-
tory care. Health services researchers should be cautious
when constructing or interpreting international compar-
isons, particularly in differentiating between actual cost
differences, differences in deﬁnition of services measured,
and national practice patterns.
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OBJECTIVES: The present study presents a Bayesian
cost-effectiveness analysis of HIV prevention in the
instance when costs and effects cannot be measured
directly. METHODS: A Bayesian approach to cost-
effectiveness analysis was illustrated using empirical data
from an HIV prevention randomized trial. We computed
incremental net health beneﬁt (INHB), and the analysis
was conducted from the societal perspective. Intervention
costs were estimated retrospectively. Clients were ran-
domized into an intervention (advocacy training) (N = 15)
or comparison condition (N = 15). Risk behavior data
were collected at baseline and three months after the end
of each intervention. In the Bayesian framework, we con-
sidered what could occur in a conceptual future study that
is an identical replicate to the one actually conducted.
Using posterior distribution of the behavior parameters,
we sampled 5000 replicates. With the use of a Bernoulli
model of HIV transmission, changes in the participants’
HIV risk were combined with HIV transmission parame-
ters (drawn from their respective prior distributions) and
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converted into an estimate of the number of HIV infec-
tions averted by the intervention. For each averted 
infection replicate, the corresponding savings in future
HIV-related medical care costs and quality-adjusted life
years (QALYs) were estimated. This sampling process was
repeated 5000 times to yield a distribution of the INHB
describing the full post-data uncertainty. RESULTS: We
obtained a positive mean INHB, 0.0008 (close to zero),
indicating that advocacy training is just slightly favored
over the comparison condition for men, assuming a
$50,000 per QALY threshold. We also displayed the
acceptability curve: to be somewhat conﬁdent of the cost-
effectiveness of advocacy training over the comparison
condition, say at 0.7 probability, one should be willing to
spend over $100,000 per QALY. CONCLUSIONS: The
Bayesian framework provides a powerful tool to the econ-
omist who intends to advise policy makers by allowing
the question—whether an intervention is cost-effective—
to be addressed directly.
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OBJECTIVE: To examine the CE of adding minipool
NAT to current blood screening (CS) of volunteer blood
donations to reduce the risk of HBV, HCV and HIV infec-
tion in the United States. METHODS: We developed 
a decision analytic model of screening volunteer blood
donations in the US based on recently published Markov
models of HBV, HCV, and HIV infection to estimate 
discounted lifetime costs and quality-adjusted life year
(QALY) gains. Infection risk (including prevalence and
the window period between antigen and antibody
detectability in the donated blood), and test sensitivities
were derived from the literature. Age-speciﬁc 10-year sur-
vival of transfusion recipients was from Vamvakas (1994)
and the age distribution from a private managed care
database for transfusions in 1995. Secondary analyses
considered alternative screening strategies. RESULTS:
The model estimated NAT would annually prevent 37,
128 and 7 transfusion-acquired cases of HBV, HCV, and
HIV respectively compared to CS alone (6.2 million trans-
fusion recipients). HCV had the greatest impact on total
QALYs and costs. Although the cost per case of HIV
avoided was 3–4 times that for HBV or HCV, the overall
impact of HIV on CE was small. Adding NAT to CS
would add 86 life years, at an incremental cost per life
year gained of $2.1M and an incremental cost per QALY
gained of $1.2M. The CS + NAT-p24 strategy dominated
CS + NAT, and had an incremental cost per QALY of $0.9
M compared to CS. Results were most sensitive to disease
incidence rates, screening test costs, estimates of window
period closure, and the age distribution of transfusion
recipients. CONCLUSIONS: The CE of adding NAT to
current screening, although not within a range considered
cost-effective for health care treatments, may be reason-
able when considered in the context of other blood-
related preventive interventions such as autologous blood
donation, and the desire for a zero tolerance level for
infections from blood transfusions.
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OBJECTIVES: The use of antiretroviral therapy has enor-
mous success in slowing down disease progression in
HIV/AIDS. Combinations of therapeutics have resulted in
declining rates for opportunistic infections and mortality.
The high costs of these medications have prompted ques-
tions about their cost-effectiveness. Most studies esti-
mating cost-effectiveness of combination antiretroviral
therapy (HAART) use data from a short period of time.
Data is often collected during six months. In this study,
the impact of using an extended study period of two years
to assess the long-term effects of HAART is investigated.
METHODS: To estimate the impact of a longer period of
data collecting, data from the HIV-database from the 
University Hospital of Groningen were used. This data-
base contains data on among others hospital admission
data, opportunistic infections and serologic markers of
over 300 patients since 1996. A Markov transition model
for disease progression was developed. Using data from 
a 2-year period, the Markov transition probabilities and
the ﬁnal Markov reward was calculated. This was com-
pared with an analysis in which data from a 6-month
period were used. RESULTS: When compared with pro-
gression rates based on 6-month data, smaller progres-
sion rates were found when the model was based on a
2-year data. The use of a 2-year data period for Markov
modelling was associated with better health outcomes 
than with a model based on 6-month data. Since the 
modelling of outcomes is closely associated with costs, 
a decline in costs was also seen. Overall, the cost-
effectiveness of HAART was more favourable when the
model was based on data from a 2-year period. CON-
CLUSIONS: The use of an extended study period for mod-
elling the long-term effect of HAART leads to signiﬁcantly
different results. It is likely that the use of a relatively 
